1. Home
  2. TMHC vs GKOS Comparison

TMHC vs GKOS Comparison

Compare TMHC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMHC
  • GKOS
  • Stock Information
  • Founded
  • TMHC 1936
  • GKOS 1998
  • Country
  • TMHC United States
  • GKOS United States
  • Employees
  • TMHC N/A
  • GKOS N/A
  • Industry
  • TMHC Homebuilding
  • GKOS Medical/Dental Instruments
  • Sector
  • TMHC Consumer Discretionary
  • GKOS Health Care
  • Exchange
  • TMHC Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • TMHC 5.9B
  • GKOS 5.8B
  • IPO Year
  • TMHC 2013
  • GKOS 2015
  • Fundamental
  • Price
  • TMHC $69.41
  • GKOS $94.21
  • Analyst Decision
  • TMHC Strong Buy
  • GKOS Strong Buy
  • Analyst Count
  • TMHC 8
  • GKOS 12
  • Target Price
  • TMHC $79.38
  • GKOS $131.17
  • AVG Volume (30 Days)
  • TMHC 1.2M
  • GKOS 1.2M
  • Earning Date
  • TMHC 07-23-2025
  • GKOS 07-30-2025
  • Dividend Yield
  • TMHC N/A
  • GKOS N/A
  • EPS Growth
  • TMHC 28.80
  • GKOS N/A
  • EPS
  • TMHC 8.67
  • GKOS N/A
  • Revenue
  • TMHC $8,403,420,000.00
  • GKOS $432,953,000.00
  • Revenue This Year
  • TMHC N/A
  • GKOS $27.88
  • Revenue Next Year
  • TMHC N/A
  • GKOS $27.76
  • P/E Ratio
  • TMHC $8.01
  • GKOS N/A
  • Revenue Growth
  • TMHC 13.77
  • GKOS 26.70
  • 52 Week Low
  • TMHC $51.90
  • GKOS $77.10
  • 52 Week High
  • TMHC $75.49
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • TMHC 62.45
  • GKOS 55.37
  • Support Level
  • TMHC $64.81
  • GKOS $88.85
  • Resistance Level
  • TMHC $69.78
  • GKOS $91.35
  • Average True Range (ATR)
  • TMHC 2.16
  • GKOS 3.10
  • MACD
  • TMHC 0.21
  • GKOS 0.79
  • Stochastic Oscillator
  • TMHC 85.83
  • GKOS 95.44

About TMHC Taylor Morrison Home Corporation

Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: